select a format

Single User License
USD 2000 INR 128240
Site License
USD 4000 INR 256480
Corporate User License
USD 6000 INR 384720

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Erectile Dysfunction-Pipeline Review, H2 2015

Erectile Dysfunction-Pipeline Review, H2 2015


  • Products Id :- GMDHC6861IDB
  • |
  • Pages: 113
  • |
  • July 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Erectile Dysfunction-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Erectile Dysfunction-Pipeline Review, H2 2015', provides an overview of the Erectile Dysfunction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Erectile Dysfunction and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Erectile Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Erectile Dysfunction Overview 10

Therapeutics Development 11

Pipeline Products for Erectile Dysfunction-Overview 11

Pipeline Products for Erectile Dysfunction-Comparative Analysis 12

Erectile Dysfunction-Therapeutics under Development by Companies 13

Erectile Dysfunction-Therapeutics under Investigation by Universities/Institutes 16

Erectile Dysfunction-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Erectile Dysfunction-Products under Development by Companies 21

Erectile Dysfunction-Products under Investigation by Universities/Institutes 23

Erectile Dysfunction-Companies Involved in Therapeutics Development 24

Acorda Therapeutics, Inc. 24

Apricus Biosciences, Inc. 25

Aprogen, Inc. 26

Bioheart, Inc. 27

Biolab Sanus Farmaceutica Ltda. 28

Corridor Pharmaceuticals Inc. 29

Futura Medical Plc 30

Hanmi Pharmaceuticals, Co. Ltd. 31

IntelGenx Corp. 32

Mezzion Pharma Co. Ltd. 33

Mitsubishi Tanabe Pharma Corporation 34

Monosol Rx, LLC 35

NAL Pharmaceuticals Ltd. 36

Pacific Therapeutics Ltd. 37

Palatin Technologies, Inc. 38

Pharmicell Co., Ltd. 39

Sagene Pharmaceuticals, Inc. 40

Suda Ltd 41

Yungjin Pharm Ind. Co., Ltd. 42

Erectile Dysfunction-Therapeutics Assessment 43

Assessment by Monotherapy Products 43

Assessment by Combination Products 44

Assessment by Target 45

Assessment by Mechanism of Action 48

Assessment by Route of Administration 50

Assessment by Molecule Type 52

Drug Profiles 54

(tramadol hydrochloride + PDE-5 Inhibitor)-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

AdipoCell-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

alprostadil-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

AP-102-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

avanafil-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

BL-214-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

cimaglermin alfa-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

HCP-1302-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

HCP-1303-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Immpocellgram-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

MED-2003-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

MED-2004-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

MED-2005-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

nitroglycerin-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

selegiline + PDE-5 Inhibitor-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

sildenafil citrate-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

sildenafil citrate-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

sildenafil citrate-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

sildenafil citrate-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

T-6932-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

tadalafil-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

tadalafil-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

tadalafil-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

TPN-171-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

TPN-729-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

TR-399-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

udenafil-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

VLFIA-330-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

YBH-1603-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

Erectile Dysfunction-Recent Pipeline Updates 91

Erectile Dysfunction-Dormant Projects 101

Erectile Dysfunction-Discontinued Products 104

Erectile Dysfunction-Product Development Milestones 105

Featured News & Press Releases 105

Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity 105

Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting 105

Nov 03, 2014: Auxilium Pharmaceuticals To Present STENDRA Data At SMSNA Scientific Meeting 106

Sep 18, 2014: VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity 106

Apr 11, 2014: VIVUS To Present Clinical Data On Avanafil at European Association of Urology 107

Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product 108

Jan 21, 2014: VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil) 108

Aug 01, 2013: VIVUS Announces Commercial Supply Agreement With Sanofi to Produce Avanafil 109

Jun 26, 2013: Vivus Announces European Approval For Spedra For Treatment Of Erectile Dysfunction 109

Jun 19, 2013: Vivus Announces Positive Results From TA-501 Clinical Trial Of Stendra For Treatment Of Men With Erectile Dysfunction 111

Appendix 112

Methodology 112

Coverage 112

Secondary Research 112

Primary Research 112

Expert Panel Validation 112

Contact Us 112

Disclaimer 113

List of Tables

Number of Products under Development for Erectile Dysfunction, H2 2015 11

Number of Products under Development for Erectile Dysfunction-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 14

Number of Products under Development by Companies, H2 2015 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H2 2015 16

Comparative Analysis by Late Stage Development, H2 2015 17

Comparative Analysis by Clinical Stage Development, H2 2015 18

Comparative Analysis by Early Stage Development, H2 2015 19

Comparative Analysis by Unknown Stage Development, H2 2015 20

Products under Development by Companies, H2 2015 21

Products under Development by Companies, H2 2015 (Contd..1) 22

Products under Investigation by Universities/Institutes, H2 2015 23

Erectile Dysfunction-Pipeline by Acorda Therapeutics, Inc., H2 2015 24

Erectile Dysfunction-Pipeline by Apricus Biosciences, Inc., H2 2015 25

Erectile Dysfunction-Pipeline by Aprogen, Inc., H2 2015 26

Erectile Dysfunction-Pipeline by Bioheart, Inc., H2 2015 27

Erectile Dysfunction-Pipeline by Biolab Sanus Farmaceutica Ltda., H2 2015 28

Erectile Dysfunction-Pipeline by Corridor Pharmaceuticals Inc., H2 2015 29

Erectile Dysfunction-Pipeline by Futura Medical Plc, H2 2015 30

Erectile Dysfunction-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015 31

Erectile Dysfunction-Pipeline by IntelGenx Corp., H2 2015 32

Erectile Dysfunction-Pipeline by Mezzion Pharma Co. Ltd., H2 2015 33

Erectile Dysfunction-Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 34

Erectile Dysfunction-Pipeline by Monosol Rx, LLC, H2 2015 35

Erectile Dysfunction-Pipeline by NAL Pharmaceuticals Ltd., H2 2015 36

Erectile Dysfunction-Pipeline by Pacific Therapeutics Ltd., H2 2015 37

Erectile Dysfunction-Pipeline by Palatin Technologies, Inc., H2 2015 38

Erectile Dysfunction-Pipeline by Pharmicell Co., Ltd., H2 2015 39

Erectile Dysfunction-Pipeline by Sagene Pharmaceuticals, Inc., H2 2015 40

Erectile Dysfunction-Pipeline by Suda Ltd, H2 2015 41

Erectile Dysfunction-Pipeline by Yungjin Pharm Ind. Co., Ltd., H2 2015 42

Assessment by Monotherapy Products, H2 2015 43

Assessment by Combination Products, H2 2015 44

Number of Products by Stage and Target, H2 2015 46

Number of Products by Stage and Mechanism of Action, H2 2015 49

Number of Products by Stage and Route of Administration, H2 2015 51

Number of Products by Stage and Molecule Type, H2 2015 53

Erectile Dysfunction Therapeutics-Recent Pipeline Updates, H2 2015 91

Erectile Dysfunction-Dormant Projects, H2 2015 101

Erectile Dysfunction-Dormant Projects (Contd..1), H2 2015 102

Erectile Dysfunction-Dormant Projects (Contd..2), H2 2015 103

Erectile Dysfunction-Discontinued Products, H2 2015 104

List of Figures

Number of Products under Development for Erectile Dysfunction, H2 2015 11

Number of Products under Development for Erectile Dysfunction-Comparative Analysis, H2 2015 12

Number of Products under Development by Companies, H2 2015 13

Number of Products under Investigation by Universities/Institutes, H2 2015 16

Comparative Analysis by Late Stage Development, H2 2015 17

Comparative Analysis by Clinical Stage Development, H2 2015 18

Comparative Analysis by Early Stage Products, H2 2015 19

Assessment by Monotherapy Products, H2 2015 43

Number of Products by Top 10 Targets, H2 2015 45

Number of Products by Stage and Top 10 Targets, H2 2015 45

Number of Products by Top 10 Mechanism of Actions, H2 2015 48

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 48

Number of Products by Top 10 Routes of Administration, H2 2015 50

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 50

Number of Products by Top 10 Molecule Types, H2 2015 52

Number of Products by Stage and Top 10 Molecule Types, H2 2015 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Erectile Dysfunction Therapeutic Products under Development, Key Players in Erectile Dysfunction Therapeutics, Erectile Dysfunction Pipeline Overview, Erectile Dysfunction Pipeline, Erectile Dysfunction Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com